U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555210) titled 'Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy' on April 21.
Brief Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and metastatic disease, are capable of causing inflammation in any organ system of the body that can lead to organ damage, dysfunction, and even death in rare cases. Some patients may suffer acute and treatable complications like joint pain, bu...